The present invention relates to a specific polyethylene terephthalate (PET) allowing to produce a stretch blow molded PET bottle having superior resistance to environmental stress cracking when the inner or outer surface of the bottle is treated with stress cracking causing chemical substances and to a method of manufacturing such specific PET. The invention also relates to a stretch blow molded bottle made of such PET and a preform of such a bottle. The invention further relates to the use of the specific PET for the manufacture of a stretch blow molded PET bottle having said superior resistance to environmental stress cracking or the manufacture of a preform of such a PET bottle.

The invention relates to a method for manufacturing a plastic container, the method comprising the following steps: o providing an injected preform, o heating the preform (S2), and o performing stretch blow molding (S3) of the preform, thereby forming the container. The preform is made of a material comprising 40 to 99.9 weight percent of Polyhydroxyalkanoate (PHA). In the heating step, the preform is brought to a temperature comprised in a range between 1 C. and 20 C. under the melting temperature of the PHA. The present invention thus makes it possible to perform ISBM of Polyhydroxyalkanoate to produce a plastic container.

A photochromic polycarbonate composition including: a polycarbonate comprising bisphenol A carbonate units; a cycloaliphatic polyester comprising units of the formula (5) wherein R is a C.sub.2-12 alkylene or a C.sub.3-12 cycloalkylene; and a photo-chromic dye; wherein the composition has a transmission of 80% or more and a haze of 3% or less, measured according to ASTM D1003 (2007) using the color space CIE1931 (Illuminant C and a 2 observer) at a thickness of 1.5 mm.

##STR00001##

Articles, including water bottle(s) having a weight from 200 to 800 grams comprising a polyester composition comprising at least one polyester which comprises: (a) a dicarboxylic acid component comprising terephthalic acid residues; optionally, aromatic dicarboxylic acid or aliphatic dicarboxylic acid residues; and (b) a glycol component comprising 30 to 40 mole % of 2,2,4,4-tetramethyl-1,3-cyclobutanediol residues; and 60 to 70 mole % of 1,4-cyclohexanedimethanol residues; wherein the total mole % of the dicarboxylic acid component is 100 mole %, and the total mole % of the glycol component is 100 mole and the inherent viscosity of the polyester is from 0.50 to 0.68 dl/g as determined in 60/40 (wt/wt) phenol/tetrachloroethane at a concentration of 0.5 g/100 ml at 25 C.; and wherein the polyester has a Tg of from 100 to 140 C.; and wherein the polyester composition contains no polycarbonate.

An injection stretch blow-molded (ISBM) container prepared by way of injection molding a tubular preform followed by reheating and concurrently stretching and blow-molding the heated preform into the container. The container and preform comprise from 70 wt. % to 97.5 wt. % of a semi-crystalline polyolefin composition comprising one or polymers selected from polyethylene polymers and polypropylene polymers and from 2.5 wt. % to 30 wt. % of an alicyclic polyolefin composition, wherein the alicyclic polyolefin composition has a glass transition temperature, Tg, of from 60 to 145 C.

An injection stretch blow-molded (ISBM) container prepared by way of injection molding a tubular preform followed by reheating and concurrently stretching and blow-molding the heated preform into the container. The container and preform comprise from 70 wt. % to 97.5 wt. % of a semi-crystalline polyolefin composition comprising one or polymers selected from polyethylene polymers and polypropylene polymers and from 2.5 wt. % to 30 wt. % of an alicyclic polyolefin composition, wherein the alicyclic polyolefin composition has a glass transition temperature, Tg, of from 60 to 145 C.

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.